InBody Co.,Ltd (KOSDAQ: 041830)

Market Cap	282.68B
Revenue (ttm)	185.34B
Net Income (ttm)	36.43B
Shares Out	13.03M
EPS (ttm)	2,796.58
PE Ratio	7.76
Forward PE	7.10
Dividend	350.00 (1.61%)
Ex-Dividend Date	Dec 27, 2024

Volume	13,271
Open	22,500
Previous Close	21,700
Day's Range	21,500 - 22,500
52-Week Range	20,850 - 30,700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About InBody Co.,Ltd

InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in bariatric, cardiology, diabetes, frailty and aging, ICU, lymphedema, nephrology, nutrition, oncology, sports medicine, and rehabilitation and physical therapy applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1996
• Employees: 312
• Stock Exchange: KOSDAQ
• Ticker Symbol: 041830

Financial Performance

In 2023, InBody Co.,Ltd's revenue was 170.35 billion, an increase of 6.47% compared to the previous year's 160.00 billion. Earnings were 36.72 billion, an increase of 8.60%.